Can-Fite
is an Israeli biopharmaceutical company with fully integrated pharmaceutical
discovery and clinical development capabilities. The company has
diverse pipeline of proprietary compounds that address inflammatory,
ophthalmic and liver diseases.
The company platform
technology utilizes the Gi protein associated A3
adenosine receptor (A3AR) as a therapeutic
target. A3AR is highly expressed in inflammatory and cancer cells
where low expression is found in normal cells.
The company pipeline
drugs are synthetic, highly specific agonists and allosteric modulators
targeting the A3 adenosine receptor. All
drugs are orally bioavailable with an excellent safety profile.
|
